Vivesto Past Earnings Performance

Past criteria checks 0/6

Vivesto's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 18.2% per year.

Key information

-8.5%

Earnings growth rate

10.6%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-18.2%
Return on equity-61.7%
Net Margin-1,766.0%
Next Earnings Update22 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vivesto makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0N4A Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 247-117730
31 Dec 237-129840
30 Sep 232-284860
30 Jun 233-340920
31 Mar 233-351950
31 Dec 223-357960
30 Sep 2213-1401010
30 Jun 2224-991070
31 Mar 2229-1181110
31 Dec 2129-1331240
30 Sep 21-184-348880
30 Jun 21-195-3541080
31 Mar 21-199-3761460
31 Dec 204-2101850
31 Oct 20205-59830
31 Jul 20205-24730
30 Apr 20206-112260
31 Jan 204-1961130
31 Oct 196-167850
31 Jul 199-210600
30 Apr 1910-201520
31 Jan 1914-1541070
31 Oct 1813-1531060
31 Jul 1813-1171060
30 Apr 1812-1181090
31 Jan 1810-1281150
31 Oct 1710-1391260
31 Jul 178-1551350
30 Apr 177-1601390
31 Jan 177-1511390
31 Oct 1616-1371410
31 Jul 1619-1391480
30 Apr 1623-1421560
31 Jan 1626-1391500
31 Oct 1518-1411360
31 Jul 1519-1241220
30 Apr 1519-1171110
31 Jan 1523-1251230
31 Oct 1426-1281290
31 Jul 1428-1201240
30 Apr 1430-1051200
31 Jan 1430-901090
31 Oct 1335-751020
31 Jul 1344-711060

Quality Earnings: 0N4A is currently unprofitable.

Growing Profit Margin: 0N4A is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0N4A is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare 0N4A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0N4A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).


Return on Equity

High ROE: 0N4A has a negative Return on Equity (-61.66%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies